APGE241115P40000
- 0.00
- 0.000.00%
Apogee Therapeutics Newsroom
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Promising Advancements and Strategic Positioning Propel Apogee Therapeutics, Inc. to a Buy Rating
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $100
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
Apogee Therapeutics Price Target Maintained With a $87.00/Share by Wedbush
Apogee Therapeutics Analyst Ratings
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $81
Buy Rating on Apogee Therapeutics' APG808: Market Potential and Treatment Advantages Amid FDA Approval Landscape
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
Apogee Therapeutics, Inc. (APGE) Receives a Buy From TD Cowen
Buy Rating for Apogee Therapeutics: Promising Prospects for Dupixent and APG808 in COPD Market
Buy Rating on Apogee Therapeutics: Promising Drug Developments and Strong Financials
Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Apogee Therapeutics, Inc. (APGE)
Apogee Therapeutics Analyst Ratings
Apogee Therapeutics (APGE.US) was first covered by B of A Securities, giving it a buy rating, with a target price of $80.00.
Buy Rating Affirmed for Apogee Therapeutics as APG777 Shows Promise and Pipeline Progresses
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics, Inc. (APGE), SAGE Therapeutics (SAGE)
Jefferies Maintains Buy on Apogee Therapeutics, Raises Price Target to $75
Buy Rating Endorsed for Apogee Therapeutics Amid Promising APG777 Phase 1 Results